Eden Radioisotopes Advances Medical Isotope Project in New Mexico
News related to:Eden Radioisotopes · 2 min read
ALBUQUERQUE, N.M., Sept. 28, 2026 /CourierPR/ -- The medical isotope production facility in Lea County, New Mexico, is set to be North America's first purpose-built reactor and processing facility. Eden Radioisotopes, the company behind the project, has made significant progress toward the development of this critical American infrastructure, supported by the State of New Mexico and key partners.
The State of New Mexico has committed to supporting Eden's planned investment of up to $1.4 billion through the Job Training Incentive Program, high-wage and rural job tax credits, and LEDA GRT Share. This project is expected to create 205 jobs statewide and generate more than $1.5 billion in economic impact over 10 years.
Eden has selected Kiewit Nuclear Solutions Co. as its nuclear engineering, procurement, and construction (EPC) partner to support the project. Sargent & Lundy, which has worked with Eden throughout the development of the facility, will continue supporting the project with architecture, engineering, and regulatory services.
Together, these milestones represent another significant step toward construction of what is planned to be North America's first purpose-built medical isotope production reactor and processing facility. The project is expected to be commercially operational in 2030.
The project is crucial as the United States remains dependent on aging reactors and overseas producers for much of its supply of medical isotopes, which are used in diagnostic imaging and targeted cancer treatment. The facility will provide a reliable, large-scale U.S. production of medical isotopes, strengthening the reliability and resilience of the U.S. medical isotope supply chain.
The project also builds on New Mexico's decades-long leadership in nuclear science and technology. Eden's reactor technology is based on research developed at Sandia National Laboratories, while the state's universities and technical workforce provide an important foundation for development of a new generation of nuclear professionals.
Eden has filed its Construction Permit Application with the U.S. Nuclear Regulatory Commission and anticipates a formal NRC decision in mid-2027. The company expects to be commercially operational in 2030.
Eden Radioisotopes is developing a purpose-built medical isotope production reactor and processing facility in Lea County, New Mexico, designed to strengthen the domestic supply of critical isotopes used in diagnostic imaging and cancer treatment. The project is expected to be commercially operational in 2030. The facility will produce isotopes used in diagnostic imaging and targeted cancer treatment, addressing the vulnerability of the U.S. medical isotope supply chain. The project also builds on New Mexico's decades-long leadership in nuclear science and technology, with the state's universities and technical workforce providing a foundation for development of a new generation of nuclear professionals. The project is expected to be commercially operational in 2030.